Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (28500)	3/10/1999 5:42:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

I suspect that non-registered means that the trials have been completed, but phase III trials are awaiting the data analysis.

To: JOEBT1 who wrote (28500)	3/10/1999 10:16:00 PM
From: Machaon	Respond to of 32384

<< The only impact of Lilly's dropping the 1st generation diabetes drugs is postponing the 10 million milestone payment for 12 to 18 months. >> Well........ it also sets testing back to preclinical retinoid drugs. It's gonna be a little while til we get there. << Pfizer will go into Phase III osteoporosis with one of the two drugs currently in Phase II. >> Any idea when this could happen? Will it be in 1999? What % does Ligand get from this? I can see why Robinson says that Targretin is their most important product. ===> Ligand is conducting three pivotal trials for the treatment of patients with cutaneous T-cell lymphoma, including one Phase III trial with Targretin(R) gel (bexarotene) 1.0% and two Phase II/III trials with Targretin(R) capsules. ===> A Phase II trial with Targretin capsules is being conducted for the treatment of patients with psoriasis. ===> Phase II/III trials are being conducted with Targretin capsules in patients with advanced lung cancer, and in patients with Kaposi's sarcoma. ===> A Phase II trial with Targretin gel for the treatment of patients with actinic keratoses and Phase IIb studies in patients with ovarian and head and neck cancers have been completed. I'm not holding my breath waiting for the ovarian, head or neck results. To me, if there were significant positive results, we would've heard something. Obviously they didn't stop the trials early due to positive results. But, the other Targretin trials, and the breast cancer trials leave me a little more optimistic. There are, unfortunately, about 180,000 cases of "advanced" breast cancer per year. Targretin showed a 72% "complete" remission of breast tumors in rats, and has shown to be effective against cancer in humans (CTCL). I don't know how big the market could be in ABC, but if the treatment is about $3,000 per year, the market size is over $500 million. Regards, Bob